Celldex Therapeutics, Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-11-01

Reporting Person: Heath-Chiozzi Margo (SVP of Regulatory Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	600	$2.78	Acquired	11847	Direct
2021-11-01	Common Stock	S	600	$41.71	Disposed	11247	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Incentive Stock Option (Right to Buy)	$2.78	M	600	Disposed	2029-06-19	Common Stock (600)	Direct

Footnotes

F1: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

F2: 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.